Literature DB >> 3150645

Differential antiproliferative activities of IFNs alpha, beta and gamma: kinetics of establishment of their antiproliferative effects and the rapid development of resistance to IFNs alpha and beta.

C M Fleischmann1, W R Fleischmann.   

Abstract

Interferons have been recognized to have potent in vitro antiproliferative activities in mouse and human systems. To further investigate the kinetics of development of interferons' antiproliferative activities, mouse B-16 melanoma cells were treated with MuIFN-alpha, MuIFN-beta or MuIFN-gamma for various initial periods of time during an 8 day cloning assay. With MuIFN-alpha and MuIFN-beta treatments, maximal expression of antiproliferative activity was attained with 2 to 4 days of interferon treatment. In contrast, with MuIFN-gamma treatment, expression of antiproliferative activity increased with progressively longer periods of time of MuIFN-gamma treatment. These results suggested that B-16 melanoma cells were initially sensitive to all three of the interferons but rapidly became resistant to MuIFN-alpha and MuIFN-beta after 2 to 4 days of treatment. This suggestion was confirmed by cell growth kinetics experiments. The cells which were resistant to the antiproliferative activity of the MuIFN-alpha remained sensitive to the antiviral activity of MuIFN-alpha, suggesting that MuIFN-alpha and MuIFN-beta regulate their antiviral and antiproliferative responses via different mechanisms. The cells which were resistant to the antiproliferative activities of MuIFN-alpha and MuIFN-beta remained sensitive to MuIFN-gamma, suggesting that they were not generally resistant to antiproliferative effects. The cells which were resistant to the antiproliferative activities of the interferons gradually lost their resistance with a half-life of 11 days when they were cultured in the absence of interferons. The differential antiproliferative actions of alpha, beta and gamma interferons observed with murine B-16 melanoma were confirmed in the human system with G-361 melanoma cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3150645

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  5 in total

1.  A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

Authors:  Daniel H Sterman; Andrew Haas; Edmund Moon; Adriana Recio; Daniel Schwed; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Emmanouil Papasavvas; Luis J Montaner; Daniel F Heitjan; Leslie Litzky; Joseph Friedberg; Melissa Culligan; Carl H June; Richard G Carroll; Steven M Albelda
Journal:  Am J Respir Crit Care Med       Date:  2011-06-03       Impact factor: 21.405

2.  A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses.

Authors:  S Y Hwang; P J Hertzog; K A Holland; S H Sumarsono; M J Tymms; J A Hamilton; G Whitty; I Bertoncello; I Kola
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 3.  Alpha interferon as an immunomodulator in the treatment of patients with tumors.

Authors:  M Alvarez-Mon; O J Salmerón; L Manzano; M Rodríguez-Zapata; E Reyes; L M Vaquer; J Carballido
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice.

Authors:  C M Fleischmann; G J Stanton; W R Fleischmann
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

5.  Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.

Authors:  Diego A Jaitin; Laila C Roisman; Eva Jaks; Martynas Gavutis; Jacob Piehler; Jose Van der Heyden; Gilles Uze; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.